Ceregene
Latest round
- Series D
Last raised
- Apr 2012
Total raised
- $71M
Investors
- 6
About Ceregene
Ceregene Inc.Founded in 2001, Ceregene Inc. operates from San Diego, US, specializing in gene therapy development for neurodegenerative conditions.000 mn.Ceregene, Inc. specializes in the development of gene therapy products aimed at treating major neurodegenerative disorders, leveraging proprietary gene delivery technology to deliver neurotrophic growth factors. Their core product offerings include therapies designed for Alzheimer's disease and Parkinson's disease, which have successfully progressed through preclinical development and into clinical trials. These therapies seek to slow, halt, or potentially reverse neuronal degeneration, addressing critical gaps in treatment for conditions that currently lack effective solutions. Ceregene's client base primarily consists of healthcare professionals and institutions focused on neurology, as well as research organizations looking to explore innovative treatment options for neurodegenerative diseases.Ceregene's revenue model is centered on partnerships with healthcare institutions and research organizations that seek advanced treatment options for neurodegenerative diseases. The company's transactions typically occur through collaborative agreements with clinical research centers, which may include joint research initiatives, clinical trials, and potential licensing agreements for the use of their proprietary gene therapy technologies. These collaborations allow Ceregene to monetize its innovative therapies while supporting the advancement of clinical research. While specific pricing details for individual products or services have not been disclosed, the revenue structure is likely structured around milestone payments, grants from research institutions, and potential royalties from successful commercialization of their gene therapies.Ceregene plans to develop new products targeting neurodegenerative diseases, although specific release dates are not provided. There are intentions to expand into international markets, particularly in regions that show a growing demand for such therapies. The recent acquisition facilitated by Sangamo BioSciences Inc.
Who invested in Ceregene
6 investors across 4 rounds
See all investors in Ceregene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ceregene
Who invested in Ceregene?
Ceregene has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ceregene raised?
Ceregene has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Ceregene last raise money?
Ceregene's most recent round on record is a Series D, in Apr 2012.
What does Ceregene do?
Ceregene is a biotechnology company.
Where is Ceregene headquartered?
Ceregene is headquartered in San Diego, US.
Which VCs invest in companies like Ceregene?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ceregene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Ceregene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.